Also trades as: THYROCARE.BO (BSE) · $vol 0M

₹531.00 ($5.51)

-3.15 (-0.59%)

NSE · Healthcare · Medical - Diagnostics & Research · Tech Score Sell · Power 41 · ₹84.5B mcap · 46M float · 1.41% daily turnover

Overview Chart Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B-

Oct 01, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. THYROCARE.NS receives an overall rating of B-. Strongest factors: DCF (4/5), ROE (5/5). Areas of concern: ROA (1/5), D/E (1/5), P/E (2/5), P/B (1/5).

Rating Change History

Date	From	To
2026-10-01	C+	B-
2026-08-11	B-	C+
2026-08-05	C	B-
2026-07-27	A-	C
2026-06-22	B+	A-
2026-05-14	A-	B+
2026-05-11	C	A-
2026-01-30	A-	C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 84 Grade A+

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

100

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. THYROCARE.NS scores highest in Safety (100/100) and lowest in Value (45/100). An overall grade of A+ places THYROCARE.NS among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

23.30

Safe Zone

Piotroski F-Score

6/9

✓ ✓ ✓ ✓ ✗ ✓ ✗ ✗ ✓

Beneish M-Score

-2.78

Unlikely Manipulator

Ohlson O-Score

-13.56

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

AAA

Score: 96.0/100

Trend: Stable

Earnings Quality

75/100

OCF/NI: 1.70x

Accruals: -15.8%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. THYROCARE.NS scores 23.30, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. THYROCARE.NS scores 6/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. THYROCARE.NS's score of -2.78 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. THYROCARE.NS's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. THYROCARE.NS receives an estimated rating of AAA (score: 96.0/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). THYROCARE.NS's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

30.96x

PEG

-2.12x

P/S

9.65x

P/B

14.42x

P/FCF

23.68x

P/OCF

19.96x

EV/EBITDA

19.52x

EV/Revenue

6.45x

EV/EBIT

24.84x

EV/FCF

22.90x

Earnings Yield

2.95%

FCF Yield

4.22%

Shareholder Yield

3.55%

Graham Number

$92.72

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 31.0x earnings, THYROCARE.NS commands a growth premium. Graham's intrinsic value formula yields $92.72 per share, 473% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

0.766

NI / EBT

Interest Burden

0.989

EBT / EBIT

EBIT Margin

0.260

EBIT / Rev

Asset Turnover

1.151

Rev / Assets

Equity Multiplier

1.272

Assets / Equity

ROE

28.8%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. THYROCARE.NS's ROE of 28.8% is driven by Asset Turnover (1.151), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

$87.69

Price/Value

3.99x

Margin of Safety

-298.62%

Premium

298.62%

Assessment

Overvalued

Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with THYROCARE.NS's realized 0.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. THYROCARE.NS trades at a 299% premium to its adjusted intrinsic value of $87.69, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 8.5x compares to the current market P/E of 31.0x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$533.60

Median 1Y

$474.93

5th Pctile

$189.68

95th Pctile

$1195.10

Ann. Volatility

56.7%

25th–75th percentile 5th–95th percentile Median path Historical

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
ROE	43.7%	45.0%	41.5%	36.9%	30.6%	16.4%	14.4%	12.1%	11.3%	13.2%	13.1%	13.3%	14.6%	17.2%	18.0%	17.1%	19.8%	25.0%	26.9%	28.8%	28.81%
ROA	33.4%	36.7%	34.4%	30.5%	24.8%	13.8%	12.2%	10.4%	9.7%	11.1%	11.0%	11.1%	12.2%	14.1%	14.7%	13.7%	15.9%	20.0%	21.6%	22.7%	22.65%
ROIC	46.6%	45.7%	41.6%	38.1%	31.4%	19.2%	17.4%	16.0%	15.0%	14.9%	14.5%	16.7%	18.0%	20.8%	21.6%	22.2%	25.6%	32.1%	35.3%	38.4%	38.42%
ROCE	51.1%	51.1%	46.9%	42.4%	34.0%	22.3%	19.6%	16.4%	15.9%	17.8%	17.9%	18.1%	19.7%	23.4%	24.9%	26.0%	28.9%	34.1%	35.3%	33.8%	33.77%
Gross Margin	67.1%	75.3%	74.4%	67.9%	69.1%	69.5%	68.1%	69.3%	71.8%	45.0%	41.9%	44.1%	45.5%	47.3%	72.8%	1.2%	71.2%	51.6%	46.5%	52.3%	52.32%
Operating Margin	38.9%	46.0%	23.9%	21.4%	21.4%	17.9%	15.9%	13.2%	18.4%	18.2%	13.4%	13.5%	19.9%	19.9%	14.9%	23.5%	24.0%	27.6%	18.5%	27.3%	27.27%
Net Margin	33.8%	44.1%	18.3%	16.3%	17.0%	11.4%	11.5%	9.2%	12.8%	13.7%	11.4%	11.5%	15.4%	15.0%	11.5%	11.6%	20.2%	22.2%	14.8%	21.0%	21.04%
EBITDA Margin	49.6%	59.3%	32.5%	30.4%	28.9%	24.6%	23.4%	20.9%	26.3%	26.8%	25.5%	24.2%	29.5%	28.5%	27.6%	33.3%	32.5%	34.4%	29.0%	35.7%	35.71%
FCF Margin	19.1%	13.6%	11.2%	11.6%	9.5%	12.0%	11.5%	14.9%	14.9%	15.1%	16.1%	16.5%	17.0%	17.1%	16.2%	16.9%	17.4%	27.7%	27.9%	28.2%	28.15%
OCF Margin	21.7%	18.2%	16.7%	17.2%	15.3%	15.3%	13.3%	16.7%	14.9%	15.1%	16.1%	19.2%	22.2%	24.5%	25.6%	25.2%	24.8%	34.7%	34.2%	33.4%	33.39%
ROE 3Y Avg	snapshot only																				19.35%
ROE 5Y Avg	snapshot only																				20.71%
ROA 3Y Avg	snapshot only																				15.35%
ROIC 3Y Avg	snapshot only																				25.61%
ROIC Economic	snapshot only																				25.12%
Cash ROA	snapshot only																				37.05%
Cash ROIC	snapshot only																				68.35%
CROIC	snapshot only																				57.62%
NOPAT Margin	snapshot only																				18.77%
Pretax Margin	snapshot only																				25.68%
R&D / Revenue	snapshot only																				0.00%
SGA / Revenue	snapshot only																				25.25%
SBC / Revenue	snapshot only																				2.92%

Valuation

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
P/E Ratio	37.45	27.57	27.71	21.09	21.40	32.90	61.25	32.68	43.85	44.48	52.23	44.30	42.18	50.69	54.61	37.86	48.43	47.86	51.88	33.88	30.962
P/S Ratio	10.46	8.95	8.81	6.31	5.51	5.15	8.59	3.99	4.92	5.27	6.18	5.48	5.51	6.83	7.32	5.05	7.13	8.02	9.02	6.67	9.648
P/B Ratio	15.63	11.61	10.57	7.05	5.78	5.34	8.72	3.94	4.92	5.93	7.03	5.95	6.22	8.72	9.81	6.35	9.43	11.45	13.37	9.44	14.422
P/FCF	54.74	65.70	78.64	54.29	57.88	42.78	74.87	26.74	33.09	34.99	38.39	33.20	32.34	39.98	45.18	29.88	40.84	28.98	32.30	23.68	23.676
P/OCF	48.13	49.20	52.80	36.56	36.09	33.71	64.65	23.87	33.09	34.99	38.39	28.54	24.80	27.88	28.58	19.99	28.73	23.11	26.40	19.96	19.959
EV/EBITDA	25.31	19.41	19.38	13.61	13.34	17.17	31.30	15.38	19.69	21.21	24.42	20.44	19.93	24.56	25.97	16.12	22.54	24.27	27.24	19.52	19.524
EV/Revenue	10.34	8.81	8.65	6.11	5.30	4.98	8.40	3.75	4.69	5.18	6.08	5.25	5.29	6.64	7.14	4.81	6.90	7.80	8.81	6.45	6.448
EV/EBIT	27.67	21.01	21.18	15.61	15.85	22.59	42.24	21.73	28.38	30.44	35.98	30.03	28.80	35.20	37.31	22.24	30.26	31.27	35.45	24.84	24.838
EV/FCF	54.10	64.65	77.24	52.56	55.63	41.36	73.17	25.12	31.49	34.35	37.80	31.78	31.01	38.86	44.06	28.44	39.52	28.18	31.54	22.90	22.902
Earnings Yield	2.7%	3.6%	3.6%	4.7%	4.7%	3.0%	1.6%	3.1%	2.3%	2.2%	1.9%	2.3%	2.4%	2.0%	1.8%	2.6%	2.1%	2.1%	1.9%	3.0%	2.95%
FCF Yield	1.8%	1.5%	1.3%	1.8%	1.7%	2.3%	1.3%	3.7%	3.0%	2.9%	2.6%	3.0%	3.1%	2.5%	2.2%	3.3%	2.4%	3.5%	3.1%	4.2%	4.22%
Price/Tangible Book	snapshot only																				11.663
EV/OCF	snapshot only																				19.308
EV/Gross Profit	snapshot only																				11.691
Acquirers Multiple	snapshot only																				26.273
Shareholder Yield	snapshot only																				3.55%
Graham Number	snapshot only																				$92.72

Leverage & Solvency

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Current Ratio	2.14	3.64	3.74	4.19	4.19	3.60	3.46	3.54	3.54	3.05	3.05	3.08	3.08	2.58	2.58	2.77	2.77	2.65	2.65	3.39	3.387
Quick Ratio	1.87	3.33	3.43	3.65	3.65	3.20	3.11	3.15	3.15	2.58	2.58	2.55	2.55	2.12	2.12	2.33	2.33	2.34	2.34	2.95	2.946
Debt/Equity	0.06	0.05	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.10	0.10	0.08	0.08	0.04	0.04	0.05	0.05	0.05	0.05	0.09	0.087
Net Debt/Equity	-0.18	-0.18	-0.19	-0.22	-0.22	-0.18	-0.20	-0.24	-0.24	-0.11	-0.11	-0.25	-0.25	-0.24	-0.24	-0.31	-0.31	-0.31	-0.31	-0.31	-0.308
Debt/Assets	0.04	0.04	0.04	0.03	0.03	0.03	0.03	0.04	0.04	0.08	0.08	0.07	0.07	0.03	0.03	0.04	0.04	0.04	0.04	0.07	0.068
Debt/EBITDA	0.10	0.08	0.08	0.08	0.09	0.12	0.14	0.18	0.18	0.35	0.34	0.29	0.27	0.11	0.10	0.12	0.11	0.10	0.10	0.19	0.185
Net Debt/EBITDA	-0.30	-0.31	-0.35	-0.45	-0.54	-0.59	-0.73	-0.99	-1.00	-0.39	-0.38	-0.91	-0.85	-0.71	-0.66	-0.81	-0.75	-0.68	-0.65	-0.66	-0.659
Interest Coverage	178.84	162.90	136.49	127.27	105.42	70.32	61.67	38.69	33.01	28.54	24.95	23.79	25.30	29.83	36.08	48.69	58.05	71.24	95.07	74.47	74.467
Equity Multiplier	1.34	1.21	1.18	1.15	1.15	1.16	1.17	1.18	1.18	1.22	1.22	1.22	1.22	1.22	1.22	1.27	1.27	1.27	1.27	1.28	1.276
Cash Ratio	snapshot only																				2.103
Debt Service Coverage	snapshot only																				94.737
Cash to Debt	snapshot only																				4.560
FCF to Debt	snapshot only																				4.605
Defensive Interval	snapshot only																				438.7 days

Efficiency & Turnover

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Asset Turnover	1.19	1.13	1.08	1.02	0.96	0.88	0.87	0.85	0.86	0.94	0.93	0.90	0.93	1.05	1.10	1.03	1.08	1.19	1.24	1.15	1.151
Inventory Turnover	8.08	7.65	7.15	5.72	5.05	6.34	7.09	5.05	5.00	6.84	8.38	7.30	8.52	9.00	8.13	3.77	3.18	4.21	5.66	7.27	7.272
Receivables Turnover	16.92	8.47	8.31	8.54	7.45	5.12	5.30	5.91	5.99	7.54	7.66	8.89	9.24	12.07	12.67	11.80	12.42	12.36	12.84	11.29	11.289
Payables Turnover	9.30	9.40	8.89	8.17	8.61	8.28	6.60	8.06	7.99	11.03	9.59	8.86	10.34	10.82	9.77	3.29	2.77	3.09	4.15	5.25	5.252
DSO	22	43	44	43	49	71	69	62	61	48	48	41	40	30	29	31	29	30	28	32	32.3 days
DIO	45	48	51	64	72	58	51	72	73	53	44	50	43	41	45	97	115	87	65	50	50.2 days
DPO	39	39	41	45	42	44	55	45	46	33	38	41	35	34	37	111	132	118	88	69	69.5 days
Cash Conversion Cycle	27	52	54	62	79	85	65	89	88	69	53	50	47	37	36	17	12	-2	5	13	13.0 days
Fixed Asset Turnover	snapshot only																				3.973
Operating Cycle	snapshot only																				82.5 days
Cash Velocity	snapshot only																				3.587
Capital Intensity	snapshot only																				0.901

Growth (YoY)

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Revenue	58.8%	50.2%	34.7%	19.0%	-8.5%	-18.4%	-13.8%	-10.6%	-3.3%	7.1%	6.2%	8.6%	11.3%	14.0%	18.2%	20.2%	21.8%	22.4%	21.1%	20.6%	20.61%
Net Income	1.8%	1.9%	1.6%	55.6%	-15.6%	-60.7%	-62.0%	-63.4%	-57.8%	-18.8%	-10.5%	9.9%	29.5%	29.5%	34.0%	29.5%	37.1%	52.2%	56.9%	77.9%	77.95%
EPS	2.0%	1.9%	1.6%	55.5%	-15.6%	-48.7%	-74.2%	-63.5%	-57.8%	-37.7%	26.5%	5.0%	27.9%	28.0%	38.3%	37.6%	38.2%	53.8%	-47.4%	-41.3%	-41.28%
FCF	-13.5%	-46.0%	-57.0%	-43.0%	-54.4%	-27.9%	-11.7%	15.0%	51.1%	34.1%	48.9%	20.0%	27.5%	29.2%	19.0%	23.0%	24.7%	98.2%	1.1%	1.0%	1.01%
EBITDA	81.9%	92.5%	74.2%	51.7%	-11.0%	-47.9%	-48.2%	-51.4%	-42.1%	-9.8%	-1.4%	14.3%	24.0%	26.2%	30.5%	39.6%	40.5%	45.5%	42.3%	33.6%	33.62%
Op. Income	96.2%	1.0%	80.7%	42.5%	-19.3%	-53.4%	-54.0%	-55.4%	-46.9%	-16.2%	-11.9%	1.1%	11.2%	17.1%	27.5%	49.1%	54.8%	65.9%	66.5%	50.6%	50.60%
OCF Growth	snapshot only																				59.52%
Asset Growth	snapshot only																				7.86%
Equity Growth	snapshot only																				7.09%
Debt Growth	snapshot only																				1.05%
Shares Change	snapshot only																				2.03%
Dividend Growth	snapshot only																				-32.12%

Growth (CAGR)

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Revenue 3Y	18.1%	17.9%	15.4%	13.5%	9.9%	6.1%	6.0%	6.7%	12.0%	9.5%	7.2%	5.0%	-0.5%	-0.1%	2.6%	5.3%	9.4%	14.3%	15.0%	16.3%	16.33%
Revenue 5Y	54.1%	33.4%	22.8%	14.1%	11.4%	9.0%	8.5%	8.1%	7.9%	7.5%	7.0%	7.3%	7.4%	7.8%	8.4%	9.7%	13.8%	12.8%	12.0%	10.9%	10.88%
EPS 3Y	21.8%	29.4%	26.9%	27.4%	16.8%	1.3%	-22.5%	-10.1%	2.1%	-2.1%	-5.5%	-15.8%	-23.0%	-25.8%	-23.3%	-19.2%	-9.3%	7.0%	-2.7%	-5.3%	-5.34%
EPS 5Y	59.7%	41.0%	30.2%	20.1%	13.5%	5.5%	-10.5%	-6.8%	-8.4%	-7.1%	-7.8%	-4.5%	-3.0%	-3.7%	-4.0%	1.0%	13.5%	13.0%	-9.3%	-13.6%	-13.59%
Net Income 3Y	21.2%	28.7%	27.0%	27.4%	16.8%	-6.9%	-11.7%	-10.0%	-0.7%	-2.1%	-4.0%	-14.5%	-22.8%	-25.5%	-23.0%	-19.6%	-9.2%	16.9%	23.5%	36.3%	36.33%
Net Income 5Y	59.3%	40.9%	29.9%	19.9%	13.2%	-0.3%	-3.4%	-7.1%	-8.7%	-7.4%	-7.0%	-3.6%	-2.7%	-3.2%	-3.8%	0.7%	11.7%	13.1%	13.2%	7.6%	7.58%
EBITDA 3Y	13.3%	17.3%	15.4%	17.1%	9.0%	-6.0%	-8.8%	-9.7%	-2.1%	-3.3%	-3.8%	-5.5%	-13.8%	-16.0%	-12.7%	-8.1%	0.3%	18.3%	22.4%	28.7%	28.69%
EBITDA 5Y	52.4%	34.4%	23.5%	15.7%	10.0%	1.0%	-1.5%	-4.9%	-5.6%	-5.4%	-4.7%	-2.2%	-1.4%	-1.1%	-0.5%	3.3%	10.3%	10.7%	10.6%	9.5%	9.47%
Gross Profit 3Y	15.4%	16.2%	14.5%	12.8%	9.8%	5.0%	4.1%	4.8%	11.6%	6.6%	1.3%	-4.5%	-13.9%	-14.1%	-7.4%	5.8%	12.3%	18.1%	16.1%	8.0%	7.95%
Gross Profit 5Y	53.0%	33.4%	23.2%	14.3%	11.4%	8.5%	7.2%	6.8%	6.8%	4.2%	1.7%	-0.3%	-2.6%	-2.0%	1.6%	9.4%	16.0%	15.7%	13.1%	6.7%	6.69%
Op. Income 3Y	14.6%	18.8%	17.9%	16.2%	7.9%	-8.1%	-11.9%	-13.9%	-5.6%	-7.6%	-9.9%	-13.7%	-21.9%	-23.0%	-19.8%	-12.4%	-3.0%	17.6%	23.2%	31.4%	31.40%
Op. Income 5Y	51.6%	32.7%	23.6%	14.2%	8.3%	-1.2%	-5.0%	-7.4%	-8.4%	-8.1%	-7.9%	-6.7%	-5.8%	-5.3%	-5.1%	-0.8%	7.7%	8.9%	9.2%	7.6%	7.58%
FCF 3Y	23.8%	10.4%	2.7%	3.5%	-4.8%	0.8%	-10.9%	-10.3%	-15.9%	-19.5%	-17.3%	-7.7%	-4.2%	7.7%	16.1%	19.3%	33.9%	50.9%	54.6%	43.7%	43.69%
FCF 5Y	53.9%	26.1%	11.1%	5.1%	-0.2%	3.0%	1.5%	6.2%	5.5%	5.4%	7.3%	8.9%	10.7%	12.1%	4.6%	1.3%	-1.1%	6.0%	7.0%	14.2%	14.24%
OCF 3Y	8.5%	2.1%	-1.4%	-0.7%	-6.1%	-8.1%	-16.1%	-13.0%	-19.2%	-21.1%	-19.0%	-4.8%	0.2%	10.3%	18.4%	19.6%	28.6%	50.3%	57.5%	46.5%	46.46%
OCF 5Y	50.6%	27.4%	12.4%	5.3%	0.1%	-2.7%	-5.9%	-2.1%	-5.0%	-5.1%	-3.3%	1.2%	5.3%	8.8%	7.4%	5.3%	3.5%	9.6%	10.1%	16.8%	16.79%
Assets 3Y	4.1%	6.0%	6.7%	8.6%	8.6%	8.3%	10.2%	10.5%	10.5%	4.2%	4.2%	5.7%	6.0%	0.8%	0.1%	4.5%	4.5%	6.0%	4.2%	5.7%	5.70%
Assets 5Y	5.7%	5.7%	6.2%	6.9%	6.9%	4.4%	5.5%	5.7%	5.7%	3.9%	3.9%	6.3%	6.3%	5.8%	5.8%	8.1%	8.1%	5.4%	5.4%	6.5%	6.48%
Equity 3Y	-3.1%	2.2%	3.8%	6.6%	6.6%	9.9%	11.4%	13.4%	13.4%	4.9%	4.9%	7.2%	9.3%	0.4%	-1.1%	1.3%	1.3%	2.7%	1.3%	3.1%	3.10%
Book Value 3Y	-2.6%	2.8%	3.7%	6.6%	6.5%	19.5%	-2.2%	13.3%	16.5%	4.9%	3.3%	5.5%	8.9%	0.0%	-1.5%	1.7%	1.1%	-6.0%	-20.2%	-28.4%	-28.41%
Dividend 3Y	13.4%	-2.8%	-12.7%	-4.4%	-39.9%	-29.1%	-47.5%	-40.2%	—	—	—	4.6%	—	—	—	59.4%	25.9%	25.1%	-2.1%	-11.7%	-11.69%

Growth Quality

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Revenue Stability	0.87	0.90	0.94	0.97	0.73	0.64	0.74	0.82	0.58	0.50	0.61	0.73	0.51	0.45	0.62	0.76	0.91	0.92	0.89	0.83	0.825
Earnings Stability	0.58	0.57	0.55	0.70	0.46	0.10	0.05	0.04	0.01	0.01	0.02	0.01	0.01	0.05	0.07	0.09	0.02	0.01	0.00	0.00	0.000
Margin Stability	0.97	0.97	0.97	0.97	0.98	0.98	0.96	0.96	0.97	0.94	0.90	0.86	0.82	0.82	0.86	0.86	0.81	0.81	0.87	0.85	0.849
Rev. Growth Consistency	0.50	0.50	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.000
Earn. Growth Consistency	0.50	0.50	0.50	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00	1.00	1.000
FCF Positive Streak	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Earnings Persistence	0.50	0.50	0.50	0.50	0.94	0.50	0.50	0.50	0.50	0.92	0.96	0.96	0.88	0.88	0.86	0.88	0.85	0.50	0.50	0.50	0.500
Earnings Smoothness	0.07	0.02	0.11	0.57	0.83	0.13	0.10	0.07	0.19	0.79	0.89	0.91	0.74	0.74	0.71	0.74	0.69	0.59	0.56	0.44	0.439
ROE Trend	0.23	0.21	0.15	0.08	-0.02	-0.13	-0.14	-0.18	-0.23	-0.16	-0.13	-0.09	-0.04	0.02	0.04	0.04	0.06	0.09	0.10	0.13	0.128
Gross Margin Trend	-0.03	0.00	0.02	0.01	0.03	0.01	-0.01	-0.00	-0.00	-0.07	-0.13	-0.20	-0.27	-0.22	-0.10	0.13	0.21	0.23	0.16	-0.06	-0.061
FCF Margin Trend	-0.06	-0.12	-0.16	-0.13	-0.18	-0.14	-0.12	-0.03	0.01	0.02	0.05	0.03	0.05	0.04	0.02	0.01	0.01	0.12	0.12	0.11	0.115
Sustainable Growth Rate	4.3%	18.6%	21.6%	17.5%	23.5%	9.6%	10.5%	8.4%	11.3%	13.2%	13.1%	8.8%	5.7%	2.6%	-1.5%	-0.7%	2.1%	-10.7%	-8.8%	-5.8%	-5.81%
Internal Growth Rate	3.4%	17.9%	21.7%	16.9%	23.5%	8.8%	9.8%	7.7%	10.7%	12.5%	12.3%	7.9%	4.9%	2.1%	—	—	1.7%	—	—	—	—

Cash Flow Quality

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
OCF/Net Income	0.78	0.56	0.52	0.58	0.59	0.98	0.95	1.37	1.33	1.27	1.36	1.55	1.70	1.82	1.91	1.89	1.69	2.07	1.97	1.70	1.698
FCF/OCF	0.88	0.75	0.67	0.67	0.62	0.79	0.86	0.89	1.00	1.00	1.00	0.86	0.77	0.70	0.63	0.67	0.70	0.80	0.82	0.84	0.843
FCF/Net Income	snapshot only																				1.431
OCF/EBITDA	snapshot only																				1.011
CapEx/Revenue	2.6%	4.6%	5.5%	5.6%	5.8%	3.2%	1.8%	1.8%	0.0%	0.0%	0.0%	2.7%	5.2%	7.4%	9.4%	8.4%	7.4%	7.0%	6.2%	5.2%	5.24%
CapEx/Depreciation	snapshot only																				0.742
Accruals Ratio	0.07	0.16	0.16	0.13	0.10	0.00	0.01	-0.04	-0.03	-0.03	-0.04	-0.06	-0.09	-0.12	-0.13	-0.12	-0.11	-0.21	-0.21	-0.16	-0.158
Sloan Accruals	snapshot only																				-0.017
Cash Flow Adequacy	snapshot only																				1.156
Earnings Quality Score	snapshot only																				0.750

Dividends & Buybacks

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Dividend Yield	2.4%	2.1%	1.7%	2.5%	1.1%	1.3%	0.4%	0.9%	0.0%	0.0%	0.0%	0.8%	1.5%	1.7%	2.0%	2.7%	1.8%	3.0%	2.6%	3.5%	1.76%
Dividend/Share	$28.67	$22.47	$17.43	$17.51	$6.23	$8.14	$2.53	$3.75	$0.00	$0.00	$0.00	$4.30	$8.89	$13.34	$17.75	$18.27	$17.92	$34.48	$11.40	$12.40	$9.33
Payout Ratio	90.2%	58.6%	48.1%	52.6%	23.2%	41.3%	27.1%	30.8%	0.0%	0.0%	0.0%	33.7%	61.4%	85.1%	1.1%	1.0%	89.5%	1.4%	1.3%	1.2%	1.20%
FCF Payout Ratio	1.3%	1.4%	1.4%	1.4%	62.8%	53.8%	33.1%	25.2%	0.0%	0.0%	0.0%	25.2%	47.0%	67.1%	89.9%	82.0%	75.5%	86.6%	82.6%	84.0%	83.98%
Total Payout Ratio	90.2%	58.6%	48.1%	52.6%	23.2%	41.3%	27.1%	30.8%	0.0%	0.0%	0.0%	33.7%	61.4%	85.1%	1.1%	1.0%	89.5%	1.4%	1.3%	1.2%	1.20%
Div. Increase Streak	1	0	0	0	0	0	0	0	—	—	—	0	0	0	0	1	1	1	1	1	1
Chowder Number	0.46	-0.08	-0.32	-0.10	-0.77	-0.71	-0.78	-0.78	—	—	—	0.21	—	—	—	3.03	1.02	1.59	0.94	1.09	1.093
Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Net Buyback Yield	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	0.0%	0.0%	0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.00%
Total Shareholder Return	2.4%	2.1%	1.7%	2.5%	1.1%	1.3%	0.4%	0.9%	0.0%	0.0%	0.0%	0.8%	1.5%	1.7%	2.0%	2.7%	1.8%	3.0%	2.6%	3.5%	3.55%

DuPont Factors

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Tax Burden (NI/EBT)	0.75	0.78	0.78	0.77	0.78	0.72	0.72	0.73	0.70	0.72	0.72	0.74	0.74	0.74	0.72	0.63	0.66	0.68	0.70	0.77	0.766
Interest Burden (EBT/EBIT)	0.99	0.99	0.99	0.99	0.99	0.98	0.98	0.97	0.97	0.97	0.97	0.96	0.96	0.96	0.97	0.98	0.98	0.99	0.99	0.99	0.989
EBIT Margin	0.37	0.42	0.41	0.39	0.33	0.22	0.20	0.17	0.17	0.17	0.17	0.17	0.18	0.19	0.19	0.22	0.23	0.25	0.25	0.26	0.260
Asset Turnover	1.19	1.13	1.08	1.02	0.96	0.88	0.87	0.85	0.86	0.94	0.93	0.90	0.93	1.05	1.10	1.03	1.08	1.19	1.24	1.15	1.151
Equity Multiplier	1.31	1.23	1.21	1.21	1.23	1.18	1.18	1.17	1.17	1.19	1.19	1.20	1.20	1.22	1.22	1.25	1.25	1.25	1.25	1.27	1.272

Per Share

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
EPS (Diluted TTM)	$31.77	$38.35	$36.22	$33.31	$26.83	$19.68	$9.34	$12.16	$11.32	$12.25	$11.81	$12.77	$14.49	$15.68	$16.34	$17.57	$20.02	$24.11	$8.59	$10.32	$10.32
Book Value/Share	$76.13	$91.05	$95.01	$99.64	$99.35	$121.32	$65.61	$100.95	$100.95	$91.87	$87.75	$95.06	$98.29	$91.15	$90.94	$104.81	$102.81	$100.81	$33.33	$37.04	$36.82
Tangible Book/Share	$57.04	$71.95	$75.95	$80.51	$80.28	$96.38	$52.68	$81.85	$81.85	$72.73	$69.47	$76.16	$78.75	$70.98	$70.82	$83.14	$81.56	$79.59	$26.32	$29.97	$29.97
Revenue/Share	$113.70	$118.14	$113.98	$111.42	$104.14	$125.78	$66.59	$99.50	$100.85	$103.31	$99.88	$103.20	$110.82	$116.38	$121.92	$131.77	$136.05	$143.91	$49.43	$52.44	$55.04
FCF/Share	$21.73	$16.09	$12.76	$12.94	$9.92	$15.14	$7.64	$14.86	$15.01	$15.57	$16.07	$17.04	$18.89	$19.88	$19.75	$22.26	$23.74	$39.83	$13.80	$14.76	$6.99
OCF/Share	$24.72	$21.48	$19.01	$19.22	$15.91	$19.20	$8.85	$16.65	$15.01	$15.57	$16.07	$19.82	$24.64	$28.51	$31.23	$33.27	$33.75	$49.95	$16.88	$17.51	$7.99
Cash/Share	$18.54	$21.11	$22.17	$26.27	$26.20	$25.86	$15.50	$28.48	$28.48	$18.77	$17.93	$31.87	$32.96	$25.69	$25.63	$36.74	$36.04	$36.31	$12.00	$14.62	$0.00
EBITDA/Share	$46.46	$53.60	$50.86	$49.98	$41.38	$36.46	$17.86	$24.27	$24.00	$25.23	$24.88	$26.49	$29.40	$31.46	$33.52	$39.28	$41.62	$46.25	$15.98	$17.32	$17.32
Debt/Share	$4.52	$4.30	$4.20	$3.92	$3.91	$4.45	$2.52	$4.40	$4.40	$8.88	$8.49	$7.64	$7.90	$3.46	$3.46	$4.73	$4.64	$4.66	$1.54	$3.21	$3.21
Net Debt/Share	$-14.02	$-16.82	$-17.97	$-22.36	$-22.29	$-21.41	$-12.98	$-24.08	$-24.08	$-9.88	$-9.44	$-24.23	$-25.06	$-22.22	$-22.17	$-32.01	$-31.40	$-31.65	$-10.47	$-11.41	$-11.41

Academic Models

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	23.299
Altman Z-Prime	snapshot only																				40.815
Piotroski F-Score	7	6	6	5	6	4	3	4	5	4	5	5	5	7	8	8	8	8	6	6	6
Beneish M-Score	-0.39	-0.37	0.13	-1.08	-1.82	-2.65	-2.49	-3.36	-2.70	-2.57	-2.62	-2.86	-2.95	-3.18	-3.28	-2.59	-2.49	-2.99	-2.64	-2.78	-2.777
Ohlson O-Score	snapshot only																				-13.558
ROIC (Greenblatt)	snapshot only																				45.69%
Net-Net WC	snapshot only																				$13.35
EVA	snapshot only																				$1151378416.01

Credit

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Credit Rating	snapshot only																				AAA
Credit Score	95.85	96.02	95.92	95.71	95.63	95.77	96.38	96.04	95.94	96.37	95.95	96.15	96.22	96.45	96.60	96.58	96.53	96.25	96.47	95.97	95.970
Credit Grade	snapshot only																				1
Credit Trend	snapshot only																				-0.613
Implied Spread (bps)	snapshot only																				50.000
Industry Credit Rank	snapshot only																				91
Sector Credit Rank	snapshot only																				91

THYROCARE.NS NSE

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Sign in to InsiderStreet